Rohit Tripathi, VP of Industry Strategy at RELEX, discusses how pharmaceutical reshoring demands end-to-end capability not ...
The 340B spread mechanism permits covered entities to retain the difference between discounted acquisition cost and commercial or Medicare reimbursement, incentivizing revenue capture rather than ...
Pharmaceutical Executive releases its 2026 Top 50 company rankings, FDA grants Bristol Myers Squibb's Zenbexus accelerated ...
Capital continues to flow toward clinical-stage and platform biotech companies, with a wave of new deals, partnerships, and ...
A senior source close to the companies denied any active or historical basis for a transaction, and both firms declined to comment on the denial. Prior speculation centered on preliminary discussions ...
A funding roundup covers new IPO and Series A raises across Silence Therapeutics, AbCellera, Beyang Therapeutics, and Remepy, Tyler Seville of ADVI examines the policy concerns building around the ...
Last week, reports emerged of a potential merger between AstraZeneca and Bristol Myers Squibb. While a senior source reportedly debunked these rumors days later, the news caused an uproar across the ...
FDA authorization covers adults ≥50, positioning mFLUSIVA as Moderna’s first mRNA influenza vaccine and expanding its US ...
In July of this year, Krieger Scientific issued a release addressing the increase in 303 drug warning letters issued by FDA. In 2025, as new leadership took over the agency, FDA sent 303 drug warning ...
Rumored tie-up implies acquirer skepticism versus target premium, with AstraZeneca shares falling sharply while BMS rose, reflecting concerns about value transfer and integration risk. A major ...
A changing of the guard atop Pharm Exec’s latest listing of the top biopharma Rx revenue producers reflects an industry being remade in real time, becoming as much a map of franchise quality and ...
In today's Pharmaceutical Executive Daily, Jazz Pharmaceuticals agrees to acquire Actio Biosciences, Novo Nordisk, Innate Pharma, and Innovent Biologics strike a trio of new partnerships, and a Veeva ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results